UsAgainstAlzheimer’s Applauds FDA Approval of Leqembi for Treatment of Early-Stage Alzheimer’s

<p>Medicare must now provide coverage for patients Washington, DC, July 06, 2023 (GLOBE NEWSWIRE) — Patient advocacy organization UsAgainstAlzheimer’s today hailed the first-of-its-kind traditional approval by the Food and Drug Administration (FDA) of lecanemab (marketed as Leqembi), a treatment for early-stage Alzheimer’s. This historic development brings a treatment option and renewed hope for continued innovation […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/usagainstalzheimers-applauds-fda-approval-of-leqembi-for-treatment-of-early-stage-alzheimers/">UsAgainstAlzheimer’s Applauds FDA Approval of Leqembi for Treatment of Early-Stage Alzheimer’s</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>